ACER3 enzyme may be therapeutic target in cholestasis: Lab study
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
Preventive treatment with cilnidipine and bexarotene significantly reduced markers of inflammation, liver damage, and oxidative stress, a type of cellular damage, in a rat model…
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…
An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
I’ve often wondered how and when we’ll tell our daughter Eva that she has progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. Most…
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…